FMW Media Work announces that its "New to The Street Leadership,"
Powered by Sector SPDR ETFs, will air on Bloomberg TV as sponsored
programming on Saturday, February 24, 2024, at 6:30 PM ET, and the
"New to The Street" business show will air on the FOX Business
Network, Monday, February 26, 2024, at 10:30 PM PT.
The "New to The Street Leadership" show
airs on Bloomberg TV as sponsored programming on
Saturday, February 24, 2024, at 6:30 PM ET.
"New to The Street Leadership's" TV Co-Host Matt Doherty,
Executive Coach, Media Personality, and Author, and TV Business
Co-Host Jane King talks with two inspirational business
leaders:
1). Tucker York, the Global Head of Goldman Sachs Wealth
Management of The Goldman Sachs Group, Inc. ($GS).
2). Tim Pernetti, President of IMG Academy.
New to The Street Leadership's TV Co-hosts Matt Doherty and Jane
King, from the Nasdaq MarketSite Studio, talk with Tucker York
about his leadership role as the Global Head of Goldman Sachs
Wealth Management division of The Goldman Sachs Group, Inc. ($GS)
("Goldman Sachs"). Since its inception in 1869, Goldman Sachs, a
world-renowned investment banking firm, has prided itself on
integrity, transparency, and investment performance, always looking
to improve client relationships, employee atmosphere, and
shareholder value. Tucker began his career with Goldman Sachs
shortly after graduating from business school. In October 1987,
Tucker was still a junior with Goldman when the October "Black
Market" crash occurred. Since that day, that experience changed him
forever in how he views clients' needs. With many years of
dedicated expertise assisting Goldman's clients, Tucker became a
managing director and partner at the firm in 1996 and 2000. Tucker
informs viewers that Goldman always looks at risk management
models, sharing those plans with its customers, employees, and
shareholders. Good leaders want to find immediate solutions with
the lowest possible losses that can sometimes come from unexpected
events. Tucker's leadership skills have developed over the decades
since 1987, and now, as the Global Head of Wealth Management,
Tucker always looks for ways to improve client services, better
interaction with employees, and strengthen shareholders' results
and relations. Through comprehensive risk management plans, Goldman
Sachs successfully navigated and maintained clients' confidence
through some of the worst market events, 911, Housing Crises, and
COVID-19. Risk management employees constantly look at "the what
if" scenarios to put in place platforms to ensure the needs of
their clients when adverse market events occur. Employee retention
is an integral part of the overall success at Goldman Sachs. Happy
employees engaged in ongoing operations are successfully servicing
Goldman's extensive client base. Goldman Sachs has a minimal
employee turnover rate, with many employees holding positions for
decades. As a leader, he understands that change does occur, and
knowing how to handle changes and communicate effectively is vital
to building trust and long-lasting relationships. With different
market gyrations and business and personal relationship encounters,
stress can become a problem for the best of leaders. Tucker says
influential leaders manage stress by looking at the direct cause
and managing the outcome positively. The risk-reward ratio,
long-term vs. short-term, and effectively acknowledging that ratio
reduces client, employee, and shareholder stress; a good leader
will always provide risk-avert solutions to the best of their
ability, planning to diminish anxieties. The on-screen QR code is
available during the show to download more info or visit The
Goldman Sachs Group, Inc. - https://www.goldmansachs.com/ and
Goldman Sachs Wealth Management -
https://privatewealth.goldmansachs.com/us/en/home.
Tim Pernetti, the President of IMG Academy, from the Nasdaq
MarketSite Studios, talks with New to The Street Leadership's TV
Co-host Jane King about his leadership role at the prep school. As
a leading sports education brand, IMG provides access and
opportunities for student-athletes on-campus and online. The
academy's model focuses on holistic and intentional personal
development through a suite of products. A 600-acre campus in
Bradenton, Florida, offers over 1500 students a practical education
beyond just classroom instruction. The academy prides itself on a
value proposition based on 4-core components: on-campus student
life, academics, athletics, and athletic/personal development. Tim
explains that IMG Academy is more than just sports training; it
offers students practical life skills. Confidence building,
endurance training, physical fitness, leadership skills, and
mental/mindset tools are part of the educational experience. IMG is
a proper college-prep academy offering 6-12 graders a full
curriculum of studies to prepare them for college. J.J. McCarthy,
the University of Michigan quarterback who recently won the
National Football Championship, is an IMG Academy alum. He was a
student during the COVID-19 shutdown and utilized IMG's numerous
programs to help him prepare for college. As a successful
quarterback, JJ learned meditation techniques offered to him while
attending IMG. Today's students deal with social media, other
online exposures, and social complexities, which can greatly affect
demeanor and performance. IMG provides fantastic resources to
handle daily social and academic issues. Athletics, personal
development, and academics are equally balanced, giving students a
highly structured environment with the quest to ensure college and
lifetime success. Before becoming President of IMG, Tim worked as
an executive for the academy through his relationship with Endeavor
Group Holdings, Inc. In 2020, during COVID, his passion became more
evident, and he took on a direct role as president. The academy is
always looking to improve the student experience; they engage
employees, students, and parents to provide comprehensive
suggestions that can significantly benefit all the educational
platforms on campus and online. He immediately saw a need for the
academy to improve upon female programs. Girls' sports programs are
an essential aspect of the IMG Academy curriculum, with new program
offerings to inspire female athletes. Some of the most influential
female athletes sit on IMG Academy's "Women in Sports Committee,"
providing leadership roles and advice to improve girls' sports
educational experiences. Offering girls more student loan packages
has increased female enrollments and helps maintain retention
rates. The efforts proved successful with new sports curricula like
the women's volleyball program. IMG Academy hosts numerous sports
camps and college recruitment programs and has provided MLS (Major
League Soccer), NFL, WNBA, and other sports teams' facilities and
training programs. New facilities, sports programs, food services,
and student life programs became realities based on those inputs
shared with the academy's leaders. The positive ongoings have
increased student enrollment and overall student body retention.
IMG Academy's online presence, IMG Academy+, helps student-athletes
globally with various programs. Endeavor Group Holdings, Inc.
recently sold the IMG Academy to Hong Kong-based BPEA Equity (BPEA
EQT), a private equity firm. BPEA EQT, in partnership with existing
portfolio company Nord Anglia Education, can open IMG Academy's
sports educational programs to a larger global market. With Tim's
strong vision, leadership skills, and commitment to ensuring a
unique sports educational experience, IGM Academy attracts some of
the best student-athletes, helping them excel in their life's
journey. The on-screen QR code is available during the show;
download or visit IMG Academy -
https://www.imgacademy.com/.
New to The Street's nationally
broadcasted TV show airs on the Fox Business Network on Monday,
February 26, 2024, at 10:30 PM PT.
New to The Street features the following six (6) Corporate
interviews:
1). Biopharmaceutical - Tonix Pharmaceuticals,
Inc.'s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth
Lederman, MD, Chairman and CEO.
2). "Game Changers Segment" interview with
PetVivo Holdings, Inc.'s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV)
interview with John Lai, CEO/President.
3). Sustainable Solutions - VRM BioLogik® Group's (VRM)
interview with Ken Bellamy, Founder and President.
4). Biopharmaceutical -Acurx Pharmaceuticals, Inc.'s (NASDAQ:
ACXP) ($ACXP) interview with David Luci, President/CEO.
5). Coffee - NuZee, Inc.'s (NUZE) ($NUZE) interview with
Masateru Higashida, Founder, Chairman, and CEO.
6). "Sekur Privacy & Sekur Security – Weekly
Hack” segment with internet privacy expert Mr. Alain
Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR)
(FRA: GDT0) ($SWISF).
From the Nasdaq MarketSite Studio, Dr. Seth Lederman, MD,
Chairman and CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP)
($TNXP) ("Tonix"), talks with New to The Street's TV Host Jane King
about the Company's successful completion of Phase 3 studies on its
fibromyalgia drug. Tonix's new drug, called Tonmya™, is a new class
of medicine that controls pain in those who have fibromyalgia. The
drug is a non-opioid, non-addictive painkiller. Since 2009, there
have been no new fibromyalgia drugs available in the marketplace.
Fibromyalgia is common in women who have been unsuccessful in
finding current marketplace drugs limited in treatment success.
Competitor drugs cause sleeplessness and low energy. Clinical
studies have shown that Tonmya™ can eliminate most pain, enhance
sleep, and diminish patient fatigue. The side effects are minimal,
with around 3% of patients experiencing headaches and some
drowsiness. Administered as a sublingual tablet, Tonmya™ has caused
tongue numbness in a few patients. Patients take the drug at
bedtime, which can block brain signals that are often associated
with pain, and the drug has shown improved sexual functionality.
Dr. Ledermen expects the Company to submit its full report to the
FDA for market approval sometime during the first half of 2024,
with a full approval expectation sometime in 2025. The on-screen QR
code is available during the shows; download or visit Tonix
Pharmaceuticals, Inc. - https://www.tonixpharma.com/.
New to The Street airs its "Game Changers
Segment" with TV Host and Multi-media Journalist Ana
Berry, who talks with John Lai, CEO/President of PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) ("PetVivo"). With
creative therapeutic medical innovations for pets, PETV is a "Game
Changer." Owners of dogs, cats, and horses are seeing remarkable
results when using the Company's SPRYNG™ with OsteoCushion
Technology ("SPRYNG™"), an intra-articular injectable veterinary
medical device consisting of cellular matrix microparticles.
Veterinarians are increasingly using the product as an alternative
to surgery, helping pet owners manage pets with osteoarthritis and
other joint-related ailments. John goes over three corporate
milestones. First, in October 2023, veterinarians presented
SPRYNG™'s positive study results on dogs with cranial cruciate
ligament (CCL) disease. The next milestone was the Company's
ability to attract Covetrus North America, LLC, another largest
veterinarian medical distributor; now, the three largest medical
distributors carry SPRYNG™. In January 2024, the third milestone
veterinarian doctors who were keynote speakers at the Veterinary
Meeting & Expo (VMX) conference in Orlando, Florida, endorsing
their successful use of the Company's SPRYNG™ product in small
animal cases. Also, Ethos Veterinary Health,
LLC's study on canine hip dysplasia using the
product shows success, giving more veterinary doctors information
about product uses. The Company expects sales increases for product
uses for small pets, dogs, and cats, as these recent studies,
presentations, and distributors are educating pet owners and vets
about SPRYNG™ positive treatment outcomes. The Company has five
more pending studies, with expected results reported before the
conclusion of 2024. PETV's SPRYNG™ with OsteoCushion Technology is
a "Game Changer" medical device that successfully treats pets and
gives owners options beyond surgeries. The on-screen QR code is
available during the show; download or visit PetVivo Holdings, Inc.
- https://petvivo.com/ & Spryng with OsteoCushion Technology -
https://www.sprynghealth.com/.
New to The Street airs TV Host Jane King's interview with VRM
BioLogik® Group's (VRM) Ken Bellamy, Founder and President. As a
leading technology company utilizing microbial formulations, VRM is
creating solutions for significant organic waste mitigation and
recycling issues facing the planet. Ken explains that using organic
catalysts and waste materials, the Company creates technologies
that improve soils, increasing agricultural productivity and water
conservation. VRM offers solutions to small growers and large
governmental organizations to recycle organic waste into usable
nutrient-rich products. Ken talks about VRM's participation in the
COP 28 event in Dubai, where they showcased innovative solutions
and case studies. VRM had the privilege of delivering a speech on
behalf of the Government of Indonesia at the event, emphasizing the
government's six years of experience and initiatives using VRM's
innovative, environmentally sound technologies, products, and
services. Currently, VRM is working with nine other countries
seeking environmentally sound solutions to improve waste management
conversion into usable products significantly. Global private and
public entities are increasingly looking to improve crop yields and
increase available agricultural acreage to eliminate food
insecurities. VRM continues to find innovative technologies that
can assist and repair the planet's ecosystem. The on-screen QR code
is available during the show; download or visit VRM BioLogik® Group
- https://www.vrm.science/.
New to The Street's TV Host Jane King from the Nasdaq MarketSite
Studio talks with David Luci, the President/CEO of Acurx
Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage
biopharmaceutical business, ACXP is developing a new class of
antibiotics for life-threatening bacterial infections. David
updates viewers on the Company's FDA Phase 2 clinical trial on
the Ibezapolstat drug, a treatment for patients with Clostridioides
difficile Infections (CDI). Based on positive data from Phase 2a
and Phase 2b, management is now going forward with the FDA Phase 3.
The Company compared its top-line data with the currently used
standard-of-care drugs in the marketplace, and Ibezapolstat has
impressive positive results. Phases 2a and 2b confirmed that the
drug had approximately 94% success with no reinfections. In treated
patients, the microbiome bacteria found in the digestive tract
shows the bacteria maintaining and restoring itself within those
patients after a 10-day treatment. At a recent microbiome
conference presentation in Texas, the Company compared logarithmic
results from a competitor drug (vancomycin) to its Ibezapolstat
drug, showing the differences in the effects on gut microbiome
bacteria. Competitor drugs have been used for decades to treat CDI,
but the reinfection rates are very high and greatly diminished gut
microbiome bacteria. ACXP's Ibezapolstat study results have shown
to combat reinfections effectively. Based on the data and other
publications regarding the market size for the newly discovered and
effective treatment of CDI, ACXP believes Ibezapolstat could be a
market worth over $1B. Decades-old antibacterial drugs are not
working due to changes in the molecular composition of CDI.
Thousands of people worldwide die annually, with many catching CDI
in hospitals and nursing homes. Acurx Pharmaceuticals, Inc.
believes its Ibezapolstat drug is the next generation for
effectively treating CDI. Throughout 2024, Investors and others
should expect more exciting news about Ibezapolstat and other
positive corporate ongoings. The on-screen QR code is available
during the show; download or visit Acurx Pharmaceuticals,
Inc. - https://www.acurxpharma.com/.
New to The Street's TV Host Jane King is at the Nasdaq
MarketSite Studio with Masateru Higashida, Founder, Chairman, and
CEO of NuZee, Inc. (NUZE) ($NUZE) ("NuZee Coffee"). The
Company leads in the co-packing for single-serve coffee formats,
helping partners and other companies enter and expand into the
single-serve coffee market. NuZee offers small coffee roasters to
more prominent global brands, an end-to-end sustainable solution
with flexibility and capacity to grow their market segments.
Consumers want high-quality coffee, an on-the-go product that NuZee
produces and sells globally, "Pour Over" and "Brew Bag" (Tea Bag
Style) single-serve coffee. Popularity for the product began in
Japan and is now gaining acceptance with US consumers. Masateru
explains the Company's single-serve Pour-Over coffee co-branding
partnership with Jimmy Butler's BIGFACE Brand. The Company has
other co-branding relationships like the one with Stone Brewing, a
prominent US craft beer company. Stone Brewing and NuZee see lots
of synergies that can expand both companies' brands. Other
opportunities exist globally as the Company evaluates direct
marketing and co-branding strategies. Management is lowering costs
from the reduced expenditures in fees paid to legal professionals,
consultants, and non-performing advertisement firms. Throughout
2024, the Company believes revenues should increase on existing
product lines from its sales/marketing campaigns while seeking more
co-branding relationships in the US and globally. NuZee is working
on new product innovations and will continue to grow its
single-serve coffee product, which can be easily portable for
travel, offices, and other events. The on-screen QR code is
available during the show; download or visit NuZee,
Inc. - https://mynuzee.com/.
Internationally acclaimed internet privacy expert Alain Ghiai,
CEO, Sekur Private Data Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0)
(Sekur®) and New to The Street TV Host / Multi-media Journalist Ana
Berry present the "Sekur Privacy & Sekur Security – The
Weekly Hack" segment. Ana and Alain discuss the topic of
news media host Tucker Carlson and his recent interview with
Russian President Vladimir Putin. Tucker Carlson has speculated
that in 2021, the US NSA unmasked his internet identity and leaked
emails to the media about his communications about interviewing the
Russian president. If it did happen, as Carlson claims, unsecured
email platforms are known to be vulnerable. Individuals and
businesses with compromised emails account for 91% of the source of
cybersecurity problems. Many individuals, companies, and
governmental entities contract Big Tech platforms for email
accounts and other technology services. When entering into
agreements with Big Tech, the "Term of Use" language often confuses
consumers, not realizing they allow technology service providers,
in some cases, authorizations to track, store, and sell data.
Recently, Google settled a lawsuit with end-users claiming web
traffic spying activities while using the "incognito" browser mode.
Alan suggests using a secure virtual private network that isn't on
a Big Tech platform. Sekur's SekurVPN services allow end-users to
appear always as operating in Switzerland, masking a subscriber's
internet footprint. SekurVPN protects subscribers' digital identity
and internet traffic as an encrypted platform. The Company and its
fully controlled servers are in Switzerland, a country with the
most stringent privacy laws. IP addresses are personal private
property, and any compromised use of data is strictly prohibited.
The Company's SekurVPN, SekurMail, and SekurMessenger
services have enhanced encrypted security features that can
significantly minimize end-users from a possible cyberattack. Alan
offers PROMO CODE: PRIVACY; subscribers can get an
additional 15% off monthly and yearly subscriptions for five years
on any of the Company's subscriptions. Sekur Private Data, Ltd.
never data mines, never sells data and never asks for a phone
number. Viewers, please tune in next time for the newest
cybersecurity topic on the "Sekur Privacy & Sekur
Security– Weekly Hack" segment. The on-screen QR code is
available during the shows to download more info or visit Sekur
Private Data, Ltd. – https://sekurprivatedata.com/,
http:/sekur.com/ and https://sekur.com/en/vpn. Privacy has
arrived!
About Goldman Sachs Wealth Management:
Goldman Sachs Wealth Management advisors offer unparalleled
resources, access, and guidance to help clients maximize their
impact and wealth. A management advisor is deeply attuned to
clients' goals and values and curates all Goldman Sachs has to
offer. Invest using a time-tested approach for managing risk and
building customized portfolios with long-term strategies for
expected future success
- https://privatewealth.goldmansachs.com/us/en/home.
About The Goldman Sachs Group, Inc. ($GS):
The Goldman Sachs Group, Inc. ($GS) is a leading global
financial institution that delivers a broad range of financial
services to a large and diversified client base, including
corporations, financial institutions, governments, and individuals.
The firm, founded in 1869, is headquartered in New York and
maintains offices in all major financial centers worldwide -
https://www.goldmansachs.com/.
About Tucker York, The Global Head of Goldman Sachs
Wealth Management:
Tucker York is the Global Head of Goldman Sachs Wealth
Management. He is a member of the Management Committee.
Mr. York also serves on the Goldman Sachs Trust Company board and
the Asset & Wealth Management Private Wealth Management
Capital Committee. Before assuming his current
role, Mr. York was Global Co-Head of the Consumer and
Wealth Management Division. Before that, he served in various
leadership roles across the global wealth
management franchise, including Head of the US
business and Co-Head of the EMEA business. Mr. York worked in
Frankfurt, Zurich, London, and New York. He began his career
covering clients in New York and continues in
that capacity today as part of his
overall responsibilities. Mr. York joined Goldman Sachs
in 1986 in New York as a Private Wealth Advisor. He was named
Managing Director in 1996 and Partner in 2000. Mr. York serves
as Vice Chair of the Network for Teaching
Entrepreneurship Board of Directors, Treasurer of the Board of
Trustees at The Marymount School, and a trustee at Christ Church in
New York City. He is also a member of the Chancellor's
Philanthropic Council at the University of North Carolina at
Chapel Hill (UNC) -
https://www.goldmansachs.com/about-us/people-and-leadership/leadership/management-committee/tucker-york.html.
About IMG Academy:
IMG Academy is the world's leading sports education brand,
providing access and opportunity for student-athletes with an
innovative suite of on-campus and online programming. IMG Academy
supports the entire student-athlete developmental journey from
exploration to specialization to graduation through its boarding
school and camps on its
cutting-edge campus in Bradenton, Florida; IMG Academy+ online
coaching with a focus on personal development through the lens of
sport and performance; and NCSA College Recruiting, providing
tools, coaching, and access to a network of 40,000 college coaches.
IMG Academy is the only education brand directly responsible for
filling one-quarter of all college roster spots annually. IMG
Academy helped place many thousands of kids into college -
https://www.imgacademy.com/.
About Tim Pernetti:
Tim Pernetti is the President of IMG Academy and is responsible
for leading the campus and all businesses in IMG Academy's physical
location in Bradenton, Florida. Tim joined IMG Academy in 2020 as
Chief Operating Officer and was later promoted to President in Aug.
2022. In his role, he led a successful navigation of the COVID-19
pandemic, keeping IMG Academy open and fully operational during a
critical time of uncertainty. Under Pernetti's leadership, IMG
Academy is on an upward trajectory of growth, including the
addition of a 15th sport (Girls Volleyball), sweeping changes to
student-athlete and staff experience, and $100M of campus capital
expansion, including the development of a state-of-the-art student
campus center, construction of a fourth dormitory and the addition
of new fields and training facilities. Before joining IMG Academy,
Pernetti was an executive at Endeavor Group Holdings, Inc.
("Endeavor") from 2015 to 2020. Serving as Executive Vice President
from 2019-20, he oversaw Endeavor and IMG sports, events, and
entertainment properties within the IMG Events & Media team in
North America and globally. Pernetti served as Chief Business
Officer of the Major League Soccer (MLS) expansion club New York
City FC (NYCFC) from 2013-2015, co-owned by Manchester City
Football Club and the New York Yankees. He is a former football
student-athlete at Rutgers University from 1989-93. Pernetti
returned to his alma mater in 2009 as the youngest Director of
Intercollegiate Athletics in college sports. From 1995 to 2009,
Pernetti held numerous executive positions in the media. After
stints as Director of Programming at ABC Sports, overseeing all
college sports, PGA Tour, and other programming relationships, and
Director of Programming & Production for ABC-TV, he was one of
the first employees for startup CSTV (College Sports Television) in
2003. Pernetti is very active in community affairs -
https://www.imgacademy.com/about-img-academy/media-brand#execs.
About Coach Matt Doherty and Doherty
Coaching:
Matt Doherty is a nationally recognized motivational speaker,
best-selling author, media personality, and executive coach. In
2022, he was named the Vistage Rookie of the Year and won the Chair
Excellence Award. He guides corporations, C-suite managers, sales
executives, and business and sports coaches to develop leadership
skills and team dynamics. Since starting on the 1982 National
Championship team with Michael Jordan at UNC, his journey has
included being the Head Coach at Notre Dame and UNC. He was named
the 2001 AP National Coach of the Year after leading the Tar Heels
to the ACC Regular Season Championship and a #1 ranking. Matt was
also the head coach at FAU and SMU and worked for ESPN, the Indiana
Pacers, and the Atlantic 10 Conference. In 2003, he embarked on a
mission to "Learn & Grow" by beginning a leadership journey at
the UVA Darden School of Business and The Wharton School. Coach
Doherty is committed to sharing universal teachings and actionable
ideas that will work for anyone -
https://www.dohertycoaching.com/.
About Sector SPDR
ETFs:
Sector SPDR ETFs are unique ETFs that divide the S&P 500
into eleven sector index funds. Investors can customize their
investments by picking and weighing each sector to meet specific
investment goals. Sector SPDR ETFs have the diversification of a
mutual fund, the focus of a sector fund, and the tradability of a
stock. Investors can buy or sell Sector SPDR ETF shares on the NYSE
Arca during trading hours. The eleven Sector SPDR ETFs represent
the S&P 500. However, each Sector SPDR ETF can be purchased
individually, providing undiluted exposure to a particular sector
or industry group - https://www.sectorspdr.com/.
About "New to The Street Leadership" with Matt Doherty
and Jane King Powered by Sector SPDR ETFs:
New to The Street Leadership with Matt Doherty and Jane King
Powered by Sector SPDR ETFs is a monthly television show featuring
individuals who lead their organization to successful outcomes and
future endeavors. Guests will share their success stories and
motivations, allowing viewers to understand and learn leadership
skills. The show is co-hosted with Coach Matt Doherty and
recognized business TV host Jane King. The show airs monthly, on
the last Saturday of each month, on Bloomberg TV as a sponsored
program - https://www.newtothestreet.com/.
About Tonix Pharmaceuticals,
Inc. (NASDAQ: TNXP)
($TNXP):
Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP)
("Tonix") is a biopharmaceutical company focused on
commercializing, developing, discovering, and licensing
therapeutics to treat and prevent human disease and alleviate
suffering. Tonix's development portfolio is focused on central
nervous system disorders. Tonix's priority is to submit a New Drug
Application (NDA) to the FDA for Tonmya, which has completed two
positive Phase 3 studies for the management of fibromyalgia. Tonix
intends to meet with the FDA in the first half of 2024 and submit
an NDA for the approval of Tonmya for the management of
fibromyalgia in the second half of 2024. TNX-102 SL is being
developed to reduce the severity of acute stress reaction and the
frequency of acute stress disorder and post-traumatic stress
disorder. This trial is being sponsored by the University of North
Carolina and received funding support from the US Department of
Defense. TNX-102 SL is also being developed to treat
fibromyalgia-type Long COVID, a chronic post-acute COVID-19
condition, and top-line results from a proof-of-concept study were
reported in the third quarter of 2023. TNX-1300 (cocaine esterase)
is a biologic designed to treat cocaine intoxication and has been
granted Breakthrough Therapy designation by the FDA and received
funding from the National Institute on Drug Abuse (NIDA). A Phase 2
study of TNX-1300 is expected to be initiated in the first quarter
of 2024. Tonix's rare disease development portfolio includes
TNX-2900 (intranasal potentiated oxytocin) for the treatment of
Prader-Willi syndrome (PWS). The FDA has granted TNX-2900 Orphan
Drug designation, and an investigational new drug (IND) application
has been cleared to support a Phase 2 study in PWS patients.
Tonix's immunology development portfolio includes biologics to
address organ transplant rejection, autoimmunity, and cancer,
including TNX-1500, which is a humanized monoclonal antibody
targeting CD40-ligand (CD40L or CD154) being developed for the
prevention of allograft rejection and for the treatment of
autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in
the third quarter of 2023. Tonix's infectious disease pipeline
includes TNX-801, a vaccine in development to prevent smallpox and
mpox. TNX-801 also serves as the live virus vaccine platform or
recombinant pox vaccine platform for other infectious diseases,
including TNX-1800, in development as a vaccine to protect against
COVID-19. During the fourth quarter of 2023, TNX-1800 was selected
by the US National Institutes of Health (NIH), National Institute
of Allergy and Infectious Diseases (NIAID) Project NextGen for
inclusion in Phase 1 clinical trials. The infectious disease
development portfolio also includes TNX-3900 and TNX-4000, which
are classes of broad-spectrum small molecule oral antivirals. Tonix
Medicines, our commercial subsidiary, markets Zembrace® SymTouch®
(sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray)
10 mg under a transition services agreement with Upsher-Smith
Laboratories, LLC from whom the products were acquired on June 30,
2023. Zembrace SymTouch and Tosymra are each indicated for the
treatment of acute migraine with or without aura in
adults.(*Tonix's product development candidates are investigational
new drugs or biologics and have not been approved for any
indication; Zembrace SymTouch and Tosymra are registered trademarks
of Tonix Medicines. All other marks are property of their
respective owners.) - https://www.tonixpharma.com/.
About PetVivo Holdings, Inc.
(NASDAQ: PETV) (NASDAQ: PETVW) ($PETV):
PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) is
an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of
animals and people. A portfolio of twenty-one patents protects the
Company's biomaterials, products, production processes and methods
of use. The Company's lead product SPRYNG™ with
OsteoCushion™ technology, a veterinarian-administered,
intra-articular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in cats, dogs
and horses, is currently available for commercial sale -
https://petvivo.com/.
About Acurx Pharmaceuticals, Inc.
(NASDAQ: ACXP) ($ACXP):
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)
($ACXP) is a clinical-stage
biopharmaceutical Company focused on developing new
antibiotics for difficult-to-treat infections. The Company's
approach is to develop antibiotic candidates that target the DNA
polymerase IIIC enzyme. Its R&D pipeline includes antibiotic
product candidates that target Gram-positive bacteria, including
Clostridioides difficile, methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and
drug-resistant Streptococcus pneumoniae (DRSP). The Company's
Ibezapolstat is a novel, orally administered antibiotic developed
as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. It is
the first of a new class of DNA polymerase IIIC inhibitors under
development by Acurx to treat bacterial infections. Ibezapolstat's
unique spectrum of activity, which includes C.
difficile but spares other Firmicutes and the important
Actinobacteria species, appears to contribute to maintaining a
healthy gut microbiome. The Company completed Phase 2 clinical
trials of Ibezapolstat. To learn more about Acurx
Pharmaceuticals and its product pipeline, please
visit www.acurxpharma.com.
About VRM Biologik:
VRM Biologik is a renowned biotech intellectual property
development leader committed to revolutionizing various industries
through innovative solutions. With a strong background in research
and development, VRM Biologik aims to create sustainable and
transformative products that address pressing global challenges.
Their sustainable technologies are designed to address
environmental challenges and promote a more sustainable future –
https://vrmbiologik.com.
About NuZee, Inc. (NUZE) ($NUZE) "NuZee
Coffee":
NuZee, Inc. (NUZE) ($NUZE) is a leading co-packing company for
single-serve coffee formats. It partners with companies to help
them expand within the single-serve and private-label coffee
categories. By providing end-to-end innovative and sustainable
solutions with the flexibility and capacity for both small roasters
and large global brands, NuZee is revolutionizing how single-serve
coffee is enjoyed in the US. Through the brand's unique process,
NuZee fulfills every aspect of co-packing needs, from sourcing,
roasting, and blending to packing and packaging -
https://mynuzee.com/.
About Sekur Private Data
Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0)
($SWISF):
Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA:
GDT0) ($SWISF) is a cybersecurity and internet privacy provider of
Swiss-hosted solutions for secure communications and secure data
management. The Company distributes a suite of secure cloud-based
storage, disaster recovery, document management, encrypted emails,
and secure communication tools. It sells its products through its
websites, www.sekur.com, approved distributors, and
telecommunication companies worldwide. Sekur Private Data, Ltd.
serves consumers, businesses, and governments worldwide -
https:/sekurprivatedata.com and https://sekur.com;
Twitter: @sekurprivate.
About New to The
Street:
New to The Street is an FMW Media production that operates one
of the longest-running US and International sponsored and
syndicated Nielsen-rated programming television brands, "New to The
Street." Since 2009, New to The Street has run biographical
interview segment shows across major U.S. television networks. The
Nielsen-rated and sponsored broadcast programming platform reaches
millions of homes in the US and international markets. FMW's New to
The Street show appears on Bloomberg and the FOX Business Network
as sponsored programming. FMW is also one of the nation's largest
buyers of linear television, long and short-form paid programming -
https://www.newtothestreet.com/.
Forward-Looking Statements Disclaimer
US/Canada:
This press release contains forward-looking statements within
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934. In some cases, you can
identify forward-looking statements by the following words:
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "ongoing," "plan," "potential," "predict,"
"project," "should," "will," "would," or the negative of these
terms or other comparable terminology. However, not all
forward-looking statements contain these words. Forward-looking
statements do not guarantee future performance or results and will
not necessarily be accurate indications of when such performance or
results are achieved. This press release should be considered in
all filings of the Companies contained in the Edgar Archives of the
Securities and Exchange Commission at www.sec.gov.
This press release contains forward-looking information within
the meaning of applicable Canadian securities laws. Forward-looking
information is often, but not always, identified by the use of
words such as "seek," "anticipate," "believe," "plan," "estimate,"
"expect," "likely," and "intend" and statements that an event or
result "may," "will," "should," "could" or "might" occur or be
achieved and other similar expressions. These statements reflect
management's current beliefs and are based on information currently
available to management as of the date hereof. Forward-looking
information in this press release includes, without limiting, the
foregoing expectations. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
CONTACT:
FMW Media Contact:Monica
Brennanmonica@NewtoTheStreet.com1-917-330-2564
"New to The Street" Business Development
Office1-516-696-5900Support@NewToTheStreet.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/48826ba7-0b59-449f-9f40-cf308f428f8a
Grafico Azioni Acurx Pharmaceuticals (NASDAQ:ACXP)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Acurx Pharmaceuticals (NASDAQ:ACXP)
Storico
Da Dic 2023 a Dic 2024